Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
Fleischmann R, Mysler E, Hall S, Kivitz AJ, Moots RJ, Luo Z, DeMasi R, Soma K, Zhang R, Takiya L, Tatulych S, Mojcik C, Krishnaswami S, Menon S, Smolen JS; ORAL Strategy investigators. Fleischmann R, et al. Among authors: tatulych s. Lancet. 2017 Jul 29;390(10093):457-468. doi: 10.1016/S0140-6736(17)31618-5. Epub 2017 Jun 16. Lancet. 2017. PMID: 28629665 Clinical Trial.
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study.
Papp KA, Krueger JG, Feldman SR, Langley RG, Thaci D, Torii H, Tyring S, Wolk R, Gardner A, Mebus C, Tan H, Luo Y, Gupta P, Mallbris L, Tatulych S. Papp KA, et al. Among authors: tatulych s. J Am Acad Dermatol. 2016 May;74(5):841-50. doi: 10.1016/j.jaad.2016.01.013. Epub 2016 Feb 19. J Am Acad Dermatol. 2016. PMID: 26899199 Free article.
Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study.
Krueger J, Clark JD, Suárez-Fariñas M, Fuentes-Duculan J, Cueto I, Wang CQ, Tan H, Wolk R, Rottinghaus ST, Whitley MZ, Valdez H, von Schack D, O'Neil SP, Reddy PS, Tatulych S; A3921147 Study Investigators. Krueger J, et al. Among authors: tatulych s. J Allergy Clin Immunol. 2016 Apr;137(4):1079-1090. doi: 10.1016/j.jaci.2015.12.1318. J Allergy Clin Immunol. 2016. PMID: 27059729 Free article. Clinical Trial.
Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis.
Feldman SR, Thaçi D, Gooderham M, Augustin M, de la Cruz C, Mallbris L, Buonanno M, Tatulych S, Kaur M, Lan S, Valdez H, Mamolo C. Feldman SR, et al. Among authors: tatulych s. J Am Acad Dermatol. 2016 Dec;75(6):1162-1170.e3. doi: 10.1016/j.jaad.2016.07.040. Epub 2016 Sep 28. J Am Acad Dermatol. 2016. PMID: 27692733 Clinical Trial.
Live Zoster Vaccine in Patients With Rheumatoid Arthritis Treated With Tofacitinib With or Without Methotrexate, or Adalimumab With Methotrexate: A Post Hoc Analysis of Data From a Phase IIIb/IV Randomized Study.
Calabrese LH, Abud-Mendoza C, Lindsey SM, Lee SH, Tatulych S, Takiya L, Iikuni N, Soma K, Luo Z, Fleischmann R. Calabrese LH, et al. Among authors: tatulych s. Arthritis Care Res (Hoboken). 2020 Mar;72(3):353-359. doi: 10.1002/acr.24010. Arthritis Care Res (Hoboken). 2020. PMID: 31207152 Free PMC article. Clinical Trial.
Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M, Bieber T, Thyssen JP, Yosipovitch G, Flohr C, Magnolo N, Maari C, Feeney C, Biswas P, Tatulych S, Valdez H, Rojo R. Simpson EL, et al. Among authors: tatulych s. Lancet. 2020 Jul 25;396(10246):255-266. doi: 10.1016/S0140-6736(20)30732-7. Lancet. 2020. PMID: 32711801 Free article. Clinical Trial.
Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies.
Dikranian AH, Gonzalez-Gay MA, Wellborne F, Álvaro-Gracia JM, Takiya L, Stockert L, Paulissen J, Shi H, Tatulych S, Curtis JR. Dikranian AH, et al. Among authors: tatulych s. RMD Open. 2022 May;8(1):e002103. doi: 10.1136/rmdopen-2021-002103. RMD Open. 2022. PMID: 35577477 Free PMC article. Clinical Trial.
Efficacy of Tofacitinib for the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis in Patient Subgroups from Two Randomised Phase 3 Trials.
Menter MA, Papp KA, Cather J, Leonardi C, Pariser DM, Krueger JG, Wohlrab J, Amaya-Guerra M, Kaszuba A, Nadashkevich O, Tsai TF, Gupta P, Tan H, Valdez H, Mallbris L, Tatulych S. Menter MA, et al. Among authors: tatulych s. J Drugs Dermatol. 2016 May 1;15(5):568-80. J Drugs Dermatol. 2016. PMID: 27168266 Clinical Trial.
14 results